
LINE LOSS ALERT: Lineage, Inc. Investors with Losses are Reminded of the September 30 Class Action Deadline – Contact BFA Law (NASDAQ:LINE)
If you invested in Lineage, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/lineage-inc-class-action-lawsuit.
Investors have until September 30, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased stock pursuant and/or traceable to Lineage's registration statement for its initial public offering held on or about July 25, 2024. The case is pending in the U.S. District Court for the Eastern District of Michigan and is captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., et al., No. 2:25-cv-12383.
Why Was Lineage Sued Under the Federal Securities Laws?
Lineage is a cold storage focused real estate investment trust ('REIT'). Through its Global Warehousing Segment, Lineage owns and operates hundreds of temperature-controlled storage facilities used by companies to store food and other perishable products.
As alleged, Lineage's IPO documents touted its 'consistent cold chain demand,' which purportedly provided Lineage 'with strong cash flows even during periods of broader economic stress.' The IPO documents also represented that the lingering effects of the COVID-19 pandemic had 'accelerated trends that . . . have the potential to be growth engines for the industry in coming years.'
In truth, Lineage was allegedly in the midst of a sustained downturn, as its customers destocked excess inventory built up during the COVID-19 pandemic, and also shifted to leaner inventories on a go-forward basis and as more cold-storage supply came on line.
Events Following the IPO
On February 26, 2025, Lineage announced its fiscal Q4 2024 financial results, revealing that customers had been 'unwinding' previously 'overbuil[t]' levels of inventory, returning to a 'more normal seasonal pattern' that was expected to 'continue moving forward.' Lineage conducted its IPO at $78 per share. Since the IPO, the price of Lineage stock has fallen dramatically, to lows near $40 per share—approximately half the IPO price.
Click here for more information: https://www.bfalaw.com/cases/lineage-inc-class-action-lawsuit.
What Can You Do?
If you invested in Lineage you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases/lineage-inc-class-action-lawsuit
Or contact:
Ross Shikowitz
[email protected]
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases/lineage-inc-class-action-lawsuit
Attorney advertising. Past results do not guarantee future outcomes.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Wall Street Journal
14 minutes ago
- Wall Street Journal
Soho House Members' Club Nearing a Deal to Go Private
A group of investors led by one of the country's biggest hotel owners is nearing a deal to take Soho House private, ending a monthslong contest over the fate of the giant members' club operator. Billionaire Ron Burkle, currently the controlling shareholder, is expected to roll over his stake, according to people familiar with the matter, along with several other existing shareholders. The new equity investors will be led by New York-based MCR Hotels, the people said.
Yahoo
42 minutes ago
- Yahoo
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid
We recently published . Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug discovery, with a focus on oncology and rare diseases. Its proprietary Recursion OS platform streamlines therapeutic identification and development. In July–August 2025, the company acquired full rights to REV102, an oral ENPP1 inhibitor from Rallybio, aimed at treating hypophosphatasia (HPP), a rare genetic disorder with no approved oral disease-modifying therapies. This acquisition expands Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s rare disease pipeline and gives it full control over a promising preclinical program. At the same time, the business streamlined its portfolio by discontinuing or pausing several programs, narrowing its focus to six active candidates, four in oncology and two in rare diseases. Its innovative AI-driven platform and pipeline have also drawn attention from investors seeking the best healthcare stocks in biotech. The corporation continues to expand its AI-driven capabilities, most notably through a collaboration with MIT to advance the Boltz-2 AI model on its BioHive-2 platform. This initiative aims to accelerate molecular discovery and synthesis, potentially shortening the path from discovery to clinical trials. The rollout of Recursion OS 2.0 and new partnerships with biopharma and data science firms further enhance its discovery and development capabilities. Copyright: dolgachov / 123RF Stock Photo Upcoming milestones in 2025 include multiple clinical trial initiations and data readouts, such as REC-617, a CDK7 inhibitor in oncology, and REC-4881 for familial adenomatous polyposis. Following its late 2024 merger with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s oncology pipeline has broadened, with several candidates expected to advance into human studies. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
42 minutes ago
- Yahoo
Clover Health (CLOV) Achieves Profitability as Medicare Advantage Membership Surges
We recently published . ABC is one of the best healthcare stocks. Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the best healthcare stocks. It is a Medicare Advantage insurer that leverages its AI-powered Clover Assistant platform to improve health outcomes, particularly for chronic conditions such as congestive heart failure. Its PPO-focused model offers broader network access compared to typical HMO plans, aiming to reduce hospitalizations and readmissions through advanced analytics and clinical decision support. In Q2 2025, Clover Health Investments, Corp. (NASDAQ:CLOV) reported a 32% year-over-year increase in Medicare Advantage membership, reaching over 106,000 members. Insurance revenue grew 34% to about $470 million, with adjusted EBITDA and net income both at roughly $17 million, maintaining profitability despite elevated sector-wide medical costs. Clover Assistant has demonstrated measurable impact, including an 18% reduction in hospitalizations and 25% fewer 30-day readmissions for heart failure patients under its care model. The business plans to use these results as a competitive differentiator and is expanding the platform to other risk-bearing organizations. Photo by National Cancer Institute on Unsplash The corporation also improved its Medicare star ratings, with PPO plans projected to rise from 3.5 stars in 2025 to 4.0 stars in 2026, boosting reimbursement potential and market competitiveness. While facing rising costs from supplemental benefits and regulatory changes, Clover Health Investments, Corp. (NASDAQ:CLOV) is pursuing cost-efficiency measures such as renegotiating partnerships and expects these efforts, along with regulatory adjustments, to help ease pressures by 2026. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.